Document is current

Article History

Received: 22 March 2026

Accepted: 7 June 2026

First Online: 6 July 2026

Declarations

:

: MPBG: Holds a consultancy or advisory role with AbbVie, AstraZeneca, Genmab, Eisai, GSK, MSD, PharmaMar, Pharma&, and Regeneron; is a speaker for AbbVie, AstraZeneca, Eisai, GSK, MSD, Pharma&, and Regeneron; and has received travel grants and accommodation from AstraZeneca, GSK, and MSD. She is the vice president of GEICO (Spanish Gynaecological Cancer Research Group [non-financial]). AG: Has received honoraria or consultation fees from GSK, MSD, AstraZeneca, Clovis, AbbVie, Eisai, and Pharma&; participated in a company-sponsored speaker’s bureau for Roche, AstraZeneca, MSD, Clovis, and GSK; and received support for travel/accommodation/expenses from Roche, MSD, GSK, AstraZeneca, and PharmaMar. AM: Has received honoraria from AstraZeneca, AbbVie, GSK, Daiichi Sankyo, Eisai, Genmab, MSD, PharmaMar, and Pharma&. EGA: Has received advisory or consultancy honoraria from AstraZeneca, MSD, Clovis Oncology, GSK, PharmaMar, Roche, Pharma&, and AbbVie; honoraria for speaker’s bureau/expert testimony from AstraZeneca, MSD, PharmaMar, Pharma&, Roche, GSK, Clovis, Eisai, and AbbVie; and support for travel/accommodation/expenses from Roche, GSK and Astra Zeneca. LGG: Has received consulting fees from Daiichi Sankyo, AbbVie, GSK, AstraZeneca, MSD, and Clovis Oncology; payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from GSK, AstraZeneca, MSD, and Eisai; support for attending meetings and/or travel from GSK, AstraZeneca, and MSD; and has participated in a data safety monitoring board or advisory board for Daiichi Sanyo. MBO: Has participated in speaking and teaching activities for GSK, MSD-AstraZeneca, Sysmex, Johnson & Johnson, Sanofi, Corza Medical, and Procare Health; advisory boards for MSD-AstraZeneca, GSK, and Johnson & Johnson; and has received support for travel and accommodation from GSK, MSD-AstraZeneca, and Procare Health. ABSH: Has received honoraria or consultation fees from AstraZeneca, MSD, and GSK; participated in a company-sponsored speaker’s bureau for AstraZeneca, MSD, GSK, and Pharma&; and received support for travel/accommodation/expenses from GSK, MSD, Roche, Pharma&, and AstraZeneca. XMG: Has participated in advisory boards for AstraZeneca, Lilly, Amgen, GSK, Janssen, Illumina, MiMark Diagnostics, MSD, Daiichi Sankyo, and AbbVie. SCB: Has participated in speaking and teaching activities for MSD-AstraZeneca, Astellas, Johnson & Johnson, Novartis, Ipsen, Eisai, and Servier; and received research funds from AstraZeneca. FC: Has participated in speaking and teaching activities for GSK, MSD, AstraZeneca, Daiichi Sankyo, Johnson & Johnson, Novartis, Jazz Pharmaceuticals, Merck, Ipsen, Jansen, Almirall, Fundación de Estudios Mastológicos, Viatris, Pfizer, Sandoz, Bayer, Incyte Biosciences Iberia, Lilly, Takeda, and Roche; in advisory boards for Merck and AstraZeneca; and has received professional or consulting fees from ASACO (Asociación de Afectadas por Cáncer de Ovario y Ginecológico). MGC, MNL, MRT, and CHR declare that they have no conflicts of interest related to the present work.

: This review article is based on published evidence and expert opinion of the authors. No new studies with human participants or animals were performed for this review.